**Past, Present, and Future Perspectives on the Systemic Therapy for Advanced Hepatocellular Carcinoma (HCC) — A Comprehensive Review**

Ahmed Abu-Zaid, Lynn Alkhatib, Judie Noemie Hoilat, Sana Samer Kadan, Abdulaziz Mohammed Eshaq, Ahmed Mubarak Fothan, Abdulrahman Mohammed Bakather, Mohammed Abuzaid, Daniah Saud Aloufi, Abdulhadi A. Alamodi and Ayman Azzam

Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/60991

#### **Abstract**

[97] Sulkowski MS, Gardiner DF, et al*.* Daclatasvir plus sofosbuvir for previously treated

[98] Molina JM, Orkin C, Iser DM, et al. All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotypes 1, 2, 3 and 4 infection in patients co-infected with HIV (PHOTON-2). 20th International AIDS Conference; July 20-25, 2014; Mel‐

[99] Pol S, Reddy KR, Baykal T et al. Interferon-free regimens of ombitasvir and ABT-450/r with or without ribavirin in patients with HCV genotype 4 infection: PEARL-I study results. [Abstract 1928.] 65th Annual Meeting of the AASLD. Novem‐

[100] Esmat GE, Shiha G, et al. Sofosbuvir plus ribavirin in the treatment of Egyptian pa‐ tients with chronic genotype 4 HCV infection. [Abstract 959.] 65th Annual Meeting of

[101] Kapoor R, Kohli A, Sidharthan S et al. All oral treatment for genotype 4 chronic hep‐ atitis C infection with sofosbuvir and ledipasvir: interim results from the NIAID SYNERGY trial. [Abstract 240.] 65th Annual Meeting of the AASLD. November 7-11,

[102] Maasoumy B, Hunyady B, et al. Performance of two HCV RNA assays during pro‐ tease inhibitor-based triple therapy in patients with advanced liver fibrosis and cir‐

[103] Martel-Laferrière V, Bichoupan K, et al. Hepatitis C direct-acting antiviral agents: changing the paradigm of hepatitis C treatment in HIV-infected patients. J Clin Gas‐

[104] R Fontana, R Bahirwani, R Reddy, et al. High efficacy and favorable safety profile of daclatasvir based all oral antiviral therapy in liver transplant recipients with severe recurrent HCV. AASLD Liver Meeting. Boston, November 7-12, 2014. AbstractLB-22.

[105] V Leroy, J Dumortier, et al. High rates of virological response and major clinical im‐ provement during sofosbuvir and daclatasvir-based regimens for the treatment of fi‐ brosing cholestatic HCV-recurrence after liver transplantation: the ANRS CO23 CUPILT Study. AASLD Liver Meeting. Boston, November 7-12, 2014. Abstract21. [106] Ghany MG, Strader DB, et al. Diagnosis, management, and treatment of hepatitis C:

or untreated chronic HCV infection. N Engl J Med. 2014;370:211-221.

bourne, Australia. Abstract MOAB0105LB.

the AASLD. November 7-11, 2014; Boston, MA.

rhosis. PLOS ONE. 2014 Nov;9(11):e110857.

an update. Hepatology*.*2009;49(4):1335-1374

troenterol. 2014 Feb;48(2):106-112.

ber 7-11, 2014; Boston, MA.

104 Recent Advances in Liver Diseases and Surgery

2014; Boston, MA.

Hepatocellular carcinoma (HCC) is the fifth most frequent cancer, the third leading cause of cancer-related mortality, and the first leading cause of death in patients with cirrhosis. Management of primary locally advanced, inoperable, recurrent or metastatic HCC is very challenging and continues to be a topic of controversy. Herein, we shed light on the past, present, and future perspectives on the systemic therapy (hormonal therapy, cytotoxic chemotherapy, and novel molecularly targeted therapy) for management of patients with advanced HCC.

**Keywords:** Hepatocellular Carcinoma
